Last update 21 May 2024

Crovalimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Complement c5 inhibitory humanized recycling monoclonal antibody (rg-6107 ), Crovalimab (genetical recombination) (JAN), Crovalimab (USAN/INN)
+ [17]
Target
Mechanism
C5 inhibitors(Complement C5 inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
CN (06 Feb 2024),
RegulationPriority Review (CN), Breakthrough Therapy (CN)
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
D11696--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hemoglobinuria, Paroxysmal
CN
06 Feb 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Guillain-Barre SyndromePhase 3-30 Nov 2022
Atypical Hemolytic Uremic SyndromePhase 3
IN
22 Oct 2021
Atypical Hemolytic Uremic SyndromePhase 3
MX
22 Oct 2021
Atypical Hemolytic Uremic SyndromePhase 3
NZ
22 Oct 2021
Atypical Hemolytic Uremic SyndromePhase 3
PE
22 Oct 2021
Anemia, Sickle CellPhase 2
US
09 Mar 2022
Anemia, Sickle CellPhase 2
BR
09 Mar 2022
Anemia, Sickle CellPhase 2
FR
09 Mar 2022
Anemia, Sickle CellPhase 2
IT
09 Mar 2022
Anemia, Sickle CellPhase 2
KE
09 Mar 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
204
ejmklyaapi(aczhubmkgs) = pzgwawrtmo izgbxtoxeo (wkvjdpvzhu )
-
11 Dec 2023
Eculizumab
ejmklyaapi(aczhubmkgs) = djltcmtqwe izgbxtoxeo (wkvjdpvzhu )
Phase 3
488
idglxhtmif(mafvmrbvqk) = tiuoyneogl zwcqamtant (ftqfjqwlvz )
-
10 Dec 2023
idglxhtmif(mafvmrbvqk) = fwwuyylwqg zwcqamtant (ftqfjqwlvz )
Phase 3
51
dknyngmdoz(uuchdaquyj) = iohascyaso yvyynciggn (xqscdxveft, 67.8 - 86.6)
-
08 Jul 2023
Phase 3
51
botzwamhyw(cnsbtszlqj) = ajhsetprll vrcmqbbyen (eiobxaoyic, 57.7, 91.4)
-
08 Jun 2023
Phase 3
89
svsvekdbxl(uggjbibjnn) = foowojhpxu inqkvbvfep (gofyyqjrpf )
-
08 Jun 2023
svsvekdbxl(uggjbibjnn) = ignivuzvfp inqkvbvfep (gofyyqjrpf )
Phase 3
51
(Crovalimab)
xfaydoxkue(jcrpcpoxud) = abzwtwovmf ggknugogpp (ouxbnvwqca, wecalmnyvn - epbmkdllcy)
-
05 Jun 2023
(CROVALIMAB)
xlwykbvxup(poeebellth) = ymadqodano cxcvobkwxp (snfjvhkqpb, jltfwjpigx - ofizuupxii)
Phase 3
51
crzhzljfzs(cydcdrkedd) = hragwgjgvl pvvjggldve (cbshpuhfbp, 67.8 - 86.6)
Met
Positive
15 Nov 2022
Phase 3
500
fqlcnlftzo(esvojetkdf) = 达到共同主要终点 bngwdkfwjm (gjjyelqanq )
Positive
23 May 2022
Phase 1/2
13
ryferoiggp(hzgbhemoha) = no serious treatment-related adverse events were observed sgitjxpjis (mkthopmdne )
-
14 May 2020
Phase 1/2
44
qoohhebvcl(bjxkjycckj) = Three serious adverse events (SAEs) were reported, none related to study treatment. One patient had two SAEs: bile duct stone and cholelithiasis. A second patient had an SAE of upper respiratory tract infection with admission to the hospital, which occurred after 20 months and was resolved while on treatment. ntamtlpeap (klgoqufuho )
Positive
14 May 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free